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Abstract.  The binding and transport of glycoalbumin 
(gA)  by the endothelium of murine myocardial micro- 
vessels were studied by perfusing in situ  ~25I-gA or 
gA-gold complexes (gA-Au) and examining the speci- 
mens by radioassays and EM, respectively. After a 3-min 
perfusion, the uptake of radioiodinated gA is 2.2-fold 
higher than that of native albumin;  it is partially 
("o55%) competed by either albumin or D-glucose, 
and almost completely abolished by the concomitant 
administration  of both competitors or by gA.  D-man- 
nose and D-galactose are not effective competitors.  Un- 
like albumin-gold complexes that bind restrictively to 
plasmalemmal vesicles, gA-Au labels the plasma- 
lemma proper, plasmalemmal  vesicles open on the 
lumen,  and most coated pits.  Competing albumin pre- 
vents gA-Au binding to the membrane of plasma- 
lemmal vesicles, while glucose significantly reduces 
the ligand binding to plasmalemma proper.  Competi- 
tion with albumin and glucose gives additive effects. 
Transcytosis of gA-Au, already detected at 3 min, be- 
comes substantial by 30 min.  No tracer exit via inter- 
cellular junctions was detected,  gA-Au progressively 
accumulates in multivesicular bodies. The results of 
the binding and competition experiments indicate that 
the gA behaves as a bifunctional ligand which is rec- 
ognized by two distinct binding  sites: one,  located on 
the plasma membrane,  binds as a  lectin the glucose 
residues of gA; whereas the other,  confined to plas- 
malemmal vesicles, recognizes presumably specific do- 
mains of the albumin molecule. 
I 
N the general  circulation,  a  small  fraction  (~<15% [14, 
19]) of the albumin is chemically and irreversibly modi- 
fied by glycation,  that is by covalent linkage of glucose 
primarily  to the e-amino groups of lysine residues (1, 8, 14, 
15,  35).  Glycated  albumin  or  glycoalbumin  (gA) ~ is  in- 
creased two- to threefold  in diabetics  and this modification 
has been connected with the vascular pathology of such pa- 
tients, especially renal and retinal microangiopathy  (4, 7, 9, 
18, 21, 24). In diabetics,  a high rate of glycation was also de- 
tected in hemoglobin (15, 21), low density lipoproteins  (18, 
51), fibrin (5), membrane proteins of erythrocytes (26, 44), 
and platelets (52), as well as in tissue and some extracellular 
matrix proteins such as collagens (4, 7, 34), fibronectin (39, 
40), nerve proteins  (43),  and lens crystallins  (27). 
Isolated  microvascular  fragments  (including  endothelial 
cells) were shown to take up gA in preference to native albu- 
min (45, 47-49). The process was ascribed to micropinocy- 
tosis by plasmalemmal  vesicles (45, 47-49) but direct evi- 
dence for this assumption  was not provided. 
Portions of this work have appeared previously in abstract form (1987. J. 
Cell Biol.  105[No.  4,  Pt. 2]:326a). 
1. Abbreviations  used in this paper: A-Au, albumin-gold; gA, glycoalbu- 
min; gA-Au, glycoalbumin-gold; MVB, multivesicular body. 
Since in our previous studies we have shown that albumin 
is  transcytosed  across  the  endothelium  by plasmalemmal 
vesicles (17, 37), it becomes of interest  to find out whether 
the same mode of transport with an expected increase in rate 
applies to gA. The work was carried out in the hopes that 
the results  will contribute to our understanding  of diabetic 
microangiopathies. 
Materials and Methods 
Animals 
The work was carried out on 168 RAP male mice, 20-30 g weight, obtained 
from the colony of the Institute of Cellular Biology and Pathology (Bucha- 
rest, Romania). The animals were kept for a week under standard housing 
conditions and feeding schedules, and deprived of food (with water given 
ad libitum)  12 h before each experiment. 
Reagents 
Reagents were obtained from the following sources: Crystallized BSA (here- 
after referred to  as albumin)  from  Miles Diagnostics Laboratories Inc. 
(Naperville, IL); Glyco-Gel B (m-aminophenyl-boronic acid-agarose) and 
Iodogen  from  Pierce Chemical  Co.  (Rockford,  IL);  [~4C]glucose  from 
Amersham Corp. (Arlington Heights, IL); tetrachloroauric acid (HAuCI4) 
and white phosphorus from BDH  Chemicals Ltd.  (Poole, England);  D- 
glucose, o-mannose, and D-galactose from Sigma Chemical Co. (St. Louis, 
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cia Fine Chemicals Inc. (Uppsala, Sweden); carrier-free Na[125I] from the 
Institute of Atomic Energy (Otwock-Swierk, Poland); and Dulbecco's PBS, 
pH 7.4,  from Gibco Laboratories (Grand Island, NY). 
Preparation and Characterization of  Probes 
gA Preparation. 25 mg native albumin dissolved in 1 ml sterile PBS, pH 
7.4,  was incubated with 90 mM o-glucose for 14 d at 37°C (28, 29). The 
mixture was repeatedly filtered through 0.22 p,m Millipore filters and exten- 
sively dialyzed against PBS to remove the unbound glucose, gA was isolated 
by boronate-affinity chromatography on a minicolumn (1 ml) of Glyco-Gel 
B previously equilibrated with ammonium acetate solution (0.25  M ammo- 
nium acetate, 0.01 M magnesium chloride, pH 8.4)  which was used both 
as sample solvent and washing medium, gA was eluted with 10 ml of 0.2 
M  No-citrate, pH 4.5 (23). Albumin in the washed (unbound) and eluted 
(bound) fractions was determined by UV absorbance at 280 nm or by pro- 
tein assays according to references 3 and 33. Boronate affinity specifically 
retains gA and allows nonglycated entities to pass through; as a result, the 
gA thus prepared is virtually free of significant amounts of native albumin 
(23). 
Aliquots of crystallized albumin dissolved in PBS (at concentrations of 
1, 2, or 3 mg/ml), subjected to the same system of boronate-affinity chroma- 
tography as above, showed that the native bovine albumin used in our ex- 
periments contained <1% gA. 
The efficiency of gA separation by boronate-affinity chromatography was 
assessed by applying to a Glyco-Gel-B column a sample of 1 ml albumin 
(25 mg) glycated with D-[14C]glucose (750,000  cpm). Protein content and 
radioactivity were determined in the eluted fractions by spectrophotometry 
at A =  280 nm and spectrometry in a gamma counter (model 4,000; Beck- 
man Instruments, Inc., Fullerton, CA), respectively. As shown in Fig.  1, 
gA is eluted as the second proteic peak which contains >85% of  the radiola- 
beled glucose. In the conditions used, 17 +  4 % of native albumin was con-  vetted  to gA. 
The extent of glycation as determined by the thiobarbituric acid method 
(52)  was 2.9  mol glucose/mol albumin, and by using [14C]glucose  (28) 
was 2.8 mol glucose/mol albumin. When incubation was performed at pH 
7.8 (2) the level of albumin glycation was increased up to 20%. 
lsoelectric Focusing. IEF carried out for 90 min at 10°C on IEF-agarose 
using Pharmalyte 3-10 (at 3,000 V, 14 W) revealed that the gA thus prepared 
was more anionic (*pI 4.45) than native (unmodified) albumin (*pI 5.2). 
These results are in agreement with data reported in references 8, 16, and 22. 
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Figure 1. Resolution of an albumin-gA mixture by boronate-aftinity 
chromatography on a Glycogel-B column. (--) O.D. 280 nm (albu- 
min);  (---)14C  radioactivity  (gA)  (counts  corrected  for  back- 
ground). Solutions for washing (WS) and elution (ES) were applied 
at the arrows with 0.25  M  NH4 acetate-0.01  M  MgC12, and 0.2 M 
No-citrate,  respectively. 
Tryptophan Fluorescence of gA. Fluorescence spectra were compara- 
tively determined for native BSA and gA. The profiles obtained revealed 
that the tryptophan fluorescence of gA is reduced by •30%  as compared 
to nonglycated albumin. In agreement with already recorded data (20, 35) 
these findings suggest that glycation  induces detectable conformational 
changes in albumin. The effect of these changes on interactions involving 
gA are still unclear. 
Radioiodination of  gA and Albumin 
Radiolabeled gA was prepared as in (12) with minor modifications. 500 I.tg 
gA in 500 ml PBS were reacted with 500 gCi Na[J2Sl] in Iodogen-coated 
test tubes (70-100 p.g Iodogen per tube). To remove unbound ~2~I, samples 
were subjected to gel filtration on Sephadex G-25 minicolumns (which were 
centrifuged at 500 g for 2 min) and then extensively dialyzed against PBS. 
~25I radioactivity per unit volume of gA solution was determined with a 
gamma counter (model 4000;  Beckman Instruments, Inc.). 
By comparison with gA, the fluorescence spectra of radioiodinated gA 
revealed  an  additional  decrease  in  tryptophan  fluorescence  (data  not 
shown). 
Radiolabeled albumin was prepared by the same procedure used for 
~25I-gA; the specific activities of the labeled proteins were '~1 p.Ci +  0.2/ 
mg protein. 
Preparation of  gA-gold (gA-Au) Complexes 
Colloidal gold suspensions of 5-nm particles were prepared by HAuCI4 
reduction with white phosphorus (38). Gold suspension was incubated for 15 
rain at 24°C with gA at a ratio of 1 ml/80 p~g. The mixture was centrifuged 
at 45,000  g  for 60 rain at 4°C and the ensuing pellet was resuspended in 
PBS to a concentration giving an A~i  °  =  1.0 (17). Before use, the tracer 
solution was centrifuged for 5 min at  12,000  g to eliminate aggregates. 
gA-Au complexes were examined by EM in negatively stained speci- 
mens. Measurements made on 120 particles gave a range of 4-7 nm for gold 
particles (with >80%  of 5-nm diameter) and a  range of 2-4 nm for the 
gA coat of gold particles visualized as a negative image, gA-Au complexes 
vary, therefore, in diameter from 6 to ! 1 nm. Albumin-gold (A-Au) com- 
plexes were prepared as in (17). 
Experimental Procedures 
General Protocol. All experiments were performed in situ and involved the 
following steps. (a) General anesthesia by i.p. injection of 5% chloralhy- 
drate (20-30 mg/100 g body weight). (b) Laparotomy followed by catheter- 
ization of abdominal aorta (to be used as inlet) and vena cava abdominalis 
(to he used as outlet) for the perfusion of the heart. (c) Perfusion with oxy- 
genated PBS at 37°C for "~4 min at a flow rate of 3 ml/min. (d) Perfusion 
of one of the following probes dissolved in PBS, and warmed up to 37°C: 
1251-gA (sp act of 1-1.5 ~Ci/~g protein) for 3  min; gA-Au at a  concen- 
tration  giving AI~  =  1.0  continuously perfused for 3,  10,  or 30  min; 
~2Sl-albumin (sp act of 1-1.5 p.Ci/p.g protein) for 3  rain;  and A-Au, the 
same amount and conditions as gA-Au. Unbound tracer was washed out by 
perfusion for 3 min at a flow rate of 3 ml/min with PBS, prewarmed to 37°C. 
Tissue Processing. At the end of the procedure described above, heart 
specimens were processed as follows. For radioassays: fresh tissue frag- 
ments were excised and prepared for spectrometry in a  gamma counter 
(model 4,000;  Beckman Instruments, Inc.);  the data obtained  were ex- 
pressed as cpm/mg wet tissue. For EM: the tissue was fixed by perfusion 
with 2.5%  formaldehyde, 1.5% glutaraldehyde, and 2.5 mM CaCI2 in 0.1 
M HCI-Na cacodylate buffer, pH 7.2. The fixative mixture was warmed up 
to 37°C and administered for 3 min at a flow rate of 3 ml/min. Excised speci- 
mens were further fixed by immersion for 60 min at l°C in a fixative mixture 
as in (36).  Fixation was followed by standard processing for EM. Thin sec- 
tions, cut on a  Reichert ultramicrotome (Reichert Scientific Instruments, 
Buffalo,  NY) or ultracut microtome (American Optical Co., Southbridge, 
MA), were lightly stained with uranyl acetate and lead citrate and examined 
with electron microscopes (models 400 HM or 201; Philips Electronic In- 
struments, Inc., Mahwah, NJ). 
Competition Experiments. Considering the special chemical nature of 
gA, the binding and uptake of either the radiolabeled or gold-conjugated 
probe was determined in various competition conditions. The binding of 
~2~l-gA, perfused for 3 min in situ, was competed with either (a) native 
albumin at 5, 20, 40, and 200 I~g/ml; (b) D-glucose at 45 and 90 mM; (c) 
200 I.tg/ml native albumin together with 90 mM glucose; (d) 100 I.tg/ml gA; 
(e)  o-mannose at 45 mM; or (f) D-galactose  at 45 mM (Fig. 2). 
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Figure 2. Quantitation of heart-associated radiolabeled tracers and 
the effect of the competitors used. First two columns, association 
(presumably binding and uptake)  of ~25I-albumin and  ~25I-glyco- 
albumin (gA) with murine hearts after 3-min perfusion in situ. The 
concentrations of the tracers in the perfusate at the beginning of the 
experiments are indicated in each column. Next eleven columns, 
the effect of competition with albumin,  glucose,  gA,  mannose, 
and galactose on t2SI-gA binding and uptake by perfused murine 
hearts. Competitor concentration is given in each column. 
The interaction of  capillary endothelium with gA-Au, perfused for 3 min 
in situ, was competed by either (a) native albumin at 20 and 40 Izg/ml; (b) 
D-glucose at 45 and 90 mM; (c) 20 gg/ml albumin together with 45 mM 
glucose; or (d) gA at 20 and 40 lag/ml. Competition with glucose was also 
carried out in experiments in which gA-Au was perfused in situ for 30 min. 
All solutions were prewarmed at 37°C and the experiment's protocol was 
the same as described above, except that,  before and during perfusion of 
the probes, the competitors were added to the perfusate. The preparation 
for radioassays and for EM was the same as indicated above. 
Morphometry. For each experimental condition involving perfusion with 
gold-conjugated probes (A-Au and gA-Au) with or without competitors, six 
specimens were randomly collected from the left ventricle. Each specimen 
was processed for transmission electron microscopy; from each specimen 
35-55  sections were obtained; and in each section capillary profiles were 
photographed and printed to final enlargements of  45,000 or 90,000x.  Each 
microvascular profile on these micrographs was used to measure the length 
of plasma membrane proper, coated pits, and plasmalemmal vesicles open 
to the luminal front, count gold particles associated with each of these do- 
mains,  and count plasmalemmal vesicles and coaled pits. Data were ex- 
pressed  as  numerical  densities  of gold particles  either  per various  en- 
dothelial cell structures or per unit length of luminal microdomain profile. 
For special measurements, additional sampling data are given in the foot- 
notes to Tables I-III. The differences between means were compared by the 
t test. 
Results 
Our  experimental  results  indicated  that  gA  and  albumin 
bound  primarily  to  the  luminal  plasmalemma  of the  en- 
dothelium of capillaries and postcapillary venules. The bind- 
ing is extensive and characteristic,  yet different for the two 
tracers.  The binding to  the  endothelium of arterioles  and 
muscular venules is limited in extent and does not exhibit a 
characteristic  pattern. 
Uptake of  Monomeric Radioiodinated gA and Albumin 
Perfusion with the same amount (10 ~tg) of '25I-albumin or 
t25I-gA followed by a PBS flash established that the amount 
of 12SI-gA (expressed  per mg  wet tissues)  retained  in  the 
tissue  is  2.2-fold  higher  than  the  amount  of  125I-albumin 
(Fig.  2). 
gA-Au and A-Au Have Different and 
Characteristic Binding Patterns 
In  experiments  with  A-Au,  the  tracer  marked  the  vast 
majority  (~97%)  of  plasmalemmal  vesicles  open  to  or 
closely associated with the luminal plasmalemma from the 
earliest time points examined in the endothelium of capillary 
and postcapillary venules. A-Au complexes appeared bound 
primarily to the vesicular membrane as already  established 
in our previous publications (17).  Binding to plasmalemma 
proper and coated pits was limited in both extent  (Table I) 
and linear density (Table  II). 
In experiments with gA-Au, the binding pattern on capil- 
lary and postcapillary venule endothelia was clearly distinct. 
Although the labeling of plasmalemmal vesicles was just as 
extensive (',~96 % of total vesicles open on the luminal front) 
and slightly more pronounced (Table II), the plasmalemma 
Table I. Comparison of  A-Au to gA-Au Binding to Endothelial Luminal Plasmalemmal 
Microdomains in Murine Myocardial Capillaries. Effects of  Competition with 
Albumin (40 #g/ml) or~and Glucose (90 mM), and gA (lO0  #g/ml) 
Plasma 
Experimental  membrane proper  % Plasmalemma 
conditions*  (% of length)  vesicles  % Coated pits§ 
A-Au  18  +  4.5  97  +  2.9  3  ±  2.0 
gA-Au  71  4-  11.2  96  +  5.1  13  +  3.1 
gA-Au competed 
by albumin*  74  +  9.1  20  +  4.7  10  +  3.3 
gA-Au competed 
by glucose*  23  +  6.1  91  +  6.3  2  +  1.0 
gA-Au competed 
by gAt  11  +  2.1  23  +_  5.1  4  5:1.5 
gA-Au competed by 
albumin  +  glucose*  13  _  3.2  14  +  3.7  3  5:1.5 
For each experimental  condition, "~ 160 gm plasmalemma  proper (luminal front), 410 plasmalemmal vesicles  open to the lumen, and 30 coated pits were examined 
(for sampling, see Morphometry). All values are mean +  SD. 
* Specimens perfused for 3 rain with each tracer. 
$ The competitors were used before and during gA-Au perfusion. 
§ All areas free of coated pits were discarded. 
Predescu et al. Endothelial Transport of Glycoalbumin  1731 Table II. Comparison of  A-Au and gA-Au Linear Density Labeling of 
Luminal Plasmalemmal  Microdomains in Murine Myocardial Capillaries. 
Effects of Competition with Albumin, Glucose, or gA* 
Gold particles/~am membrane length 
Experimental  Plasmalemma  Plasmalemma 
conditions*  proper  vesicles  Coated pits 
A-Au  9  +  3.2  67  ___  8.2  0.3  +  0.1 
gA-Au  53  +  6.1  86  +  9.1  2.0  +  0.7 
gA-Au competed 
by albumin  45  +  3.6  24  +  4.2  1.5  +  1.0 
gA-Au competed 
by glucose  18  +  2.1  79  +  10.2  0.5  +  0.3 
gA-Au competed 
by gA  10  +  3.2  20  +  3.8  2.5  +  1.0 
gA-Au competed by 
albumin  +  glucose  7  +  2.1  t7  +  4.4  2.0  +  0.5 
For the sampling and administration of competitors, see Table I and Morphometry (under Materials and Methods). All values are mean _+_ SD. 
* Specimens perfused for 3 min with each tracer. 
Concentrations given in Table I. 
proper was also heavily labeled. Approximately 70% of its 
profiles were quasicontinuously covered by gA-Au particles 
either as a monolayer or as small clusters (Fig. 3). The label- 
ing of coated pits was also more extensive (,~13 %) and heav- 
ier than that obtained by A-Au (Tables I  and II). As in the 
case of A-Au (17, 37), gA-Au binding is particularly exten- 
sive on the endothelium of capillaries and postcapillary ven- 
ules. By comparison, the binding to the endothelium of ar- 
terioles and muscular venules is almost negligible. 
Internalization of  gA-Au 
As a function of perfusion time, labeled plasmalemmal vesi- 
cles appeared throughout the endothelium from the luminal 
to the abluminal plasmalemma. The pattern of labeling var- 
ied considerably from a single to a few gA-Au particles per 
vesicle especially at early time points (3-5 min). The finding 
could  be explained  by early  internalization  during  initial 
labeling of the luminal plasmalemmal vesicles or by partial 
transfer of the gA-Au load from luminal vesicles to vesicles 
located at some depth in the cytoplasm. 
By comparison with gA-Au findings, A-Au internalization 
appeared to be less extensive, but a morphometric analysis 
was not carried out because in sections it is not always possi- 
ble to distinguish reliably surface binding  from true inter- 
nalization of markers. 
Transcytosis of  gA-Au 
In some capillaries at 3-min perfusion, some plasmalemmal 
vesicles labeled by gA-Au were found attached to or open on 
the abluminal front of the endothelium (Fig. 4). When perfu- 
sion  was extended  to  10-30  min,  gA-Au complexes were 
found on vesicles discharging on the abluminal front as well 
as in the pericapillary spaces (Fig. 4, A-D; Fig.  5 A).  As 
during internalization, the number of gA-Au complexes was 
Figure 3. Endothelial segment from a capillary  perfused  with gA-Au complexes. All plasmalemmal vesicles open on the luminal front 
are marked by the tracer which in many cases appears to be closely associated with the vesicle membrane (V~). In contradistinction with 
A-Au, gA-Au decorates the luminal plasmalemma with a quasicontinuous monolayer of particles.  Clusters of particles are found at the 
introit of some plasmalemmal vesicles (arrow). The inset illustrates the extensive character of plasmalemmal vesicle labeling: all vesicles 
in this row are labeled; variations in number of gA-Au particles per vesicle can be ascribed to the level of sectioning which is grazing 
in all cases except for the far right vesicle, e, endothelial cells;  l, lumen; s, subendothelial space. Bar, 0.1  ~rn. 
The Journal of Cell Biology, Volume 107,  1988  1732 Figure 4. Time series of the tracer binding and transport in myocardial capillaries perfused in situ with gA-Au. (.4) At 3 min, the label 
marks extensively vesicles open to the luminal front (lit) and occasionally vesicles apparently ready to open on the abluminal front of 
the endothelium (II3). There is no labeling of the intercellular space abluminal to the junction ~j) and no tracer is detected in the pericapil- 
lary space (s). l, lumen; e, endothelial cells; p, pericyte; m, muscle cells. (B and C) After 10 min, gA-Au complexes are found in variable 
number (1-9) in the profiles of vesicles apparently discharging on the abluminal front (V4). The amount of tracer (arrowhead)  already 
transported to the pericapillary spaces varies from capillary to capillary from low (B) to relatively high (C). In the pericapillary space, 
the tracer appears to be associated primarily with the basal lamina (bl). (1)) After 30 min, the tracer (arrowheads) is found in variable 
but generally large amounts in the pericapillary spaces and interstitia, and appears to be preferentially associated with the basal laminae 
(bl). In the endothelium itself, essentially all plasmalemmal vesicles irrespective of their location are labeled, l, lumen; m, muscle cells. 
Bars, 0.1  ~n. Figure 5. (A) Endothelial segment from a specimen perfused with gA-Au for 10 min. The vesicular profile (V~) seen discharging gA-Au 
particles in a narrow interstitium between the endothelium (e) and a pericyte (p) probably represents the exit from a transendothelial channel. 
That would explain the large amount of particles (arrow) associated with this element. (B) Endothelial segment from a specimen perfused 
for 10 min. The labeling pattern of plasmalemmal vesicles is as described for the previous figures. The field also includes a junction  (j) 
and associated intercellular spaces (s). The luminal infundibulum is marked by the tracer but the intercellular space abluminal to the junction 
is not. There is no tracer found in the pericapillary  space in this field. 1, lumen;  V~, vesicle open to the lumen;  V2, vesicle apparently 
internalized. (C and D) Endothelial segments from specimens perfused with gA-Au for 10 min. The figures illustrate the presence of the 
tracer in a large relatively pleomorphic vesicle assumed to be an endosome (en) and in a multivesicular body (mv). Labeling pattern of 
plasmalemmal vesicles and pericapillary space is as already described for the previous figures. C also illustrates the difference in labeling 
between luminal and abluminal plasmalemmal vesicles and the existence of an unlabeled internalized vesicle (arrow). The inset shows 
a labeled coated pit (cp) in the process of becoming a coated vesicle. Bars, 0.1  ~rn. 
lower in plasmalemmal vesicles discharging on,  or closely 
associated with, the abluminal front but the particle density 
per vesicle appeared to increase with time. 
The distribution patterns of A-Au complexes described in 
previous papers (17, 37)  and reexamined as controls in the 
present experiments were generally the  same as those de- 
scribed  above  for  transcytosis  except  that  the  amount  of 
gA-Au moved by transcytosis was higher.  A  morphometric 
analysis of transcytosis was not performed because the data 
were not considered sufficiently reliable since the label is ex- 
pected to be continuously drained from pericapillary space 
to the lymphatics. Yet, the increase mentioned above was in 
agreement with the results obtained by radioassay (Table I). 
Endocytosis of  gA-Au 
Coated pits and coated vesicles were often found labeled by 
gA-Au complexes at all perfusion times (Fig. 5 C, inset). Al- 
ready at 3 min gA-Au appeared in irregular relatively large 
pleomorphic structures with a light content tentatively iden- 
tified as endosomes (Fig. 5 C). Complexes were also found 
in  multivesicular bodies  (MVB),  structures  which  can be 
identified reliably as endosomes (Fig. 5 D). The fraction of 
MVB labeled and the density  therein  increased  with time 
(Table III). The data in Table III indicate that, depending on 
the perfusion time, about twice as many MVB were labeled 
by gA-Au than by A-Au. 
In none of the micrographs examined was the tracer found 
in elements of the endoplasmic reticulum or Golgi complex. 
Intercellular Junctions 
gA-Au complexes were found only within  the  luminal  in- 
troits of the 200 intercellular junctions examined, whereas 
the junctions proper and the intercellular spaces abluminal 
to the junction were unlabeled (Fig. 5 B). In a smaller num- 
ber of the junctions, the tracer was found within the intercel- 
lular space abluminal to the junction,  in considerably lower 
concentration than  within  the  adluminal  introit.  After ex- 
tended perfusion (30 min),  extensive labeling of the base- 
ment membrane and pericapillary spaces was localized pri- 
marily  in  phase with  endothelial  segments provided  with 
many  plasmalemmal  vesicles.  High  concentration  of  the 
tracer was not found preferentially associated with the exit 
from intercellular junctions. 
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Effects of Competition with Albumin, Glucose, or gA* 
Experimental  Percentage of MVB labeled as a function of 
conditions*  perfusion time 
3 min  10 rain  30 rain 
A-Au  12  5:3  36  5:4  39  5:3 
gA-Au  34  5:4  62  5:7  60  +  11 
gA-Au competed 
by albumin  21  5:3  ND  ND 
gA-Au competed 
by glucose  16 5:4  ND  ND 
gA-Au competed 
by gA  26 5:4.4  ND  20 5:4.0 
gA-Au competed by 
albumin +  glucose  21  5:3.5  ND  18 5:4.5 
For each experimental condition, 22-26 multivesicular bodies were examined (for the sampling, see Table II and Morphometry (under Materials and Methods). 
All values are mean +  SD. 
Concentrations given in Table I. 
Competition Studies 
Competition  of Monomeric gA  Uptake.  The binding and 
uptake of [~25I]gA were competed in parallel  studies  with 
native albumin and a number of hexoses. Native albumin at 
concentrations ranging from 5 to 200 l~g competed to the ex- 
tent of ~60%  the  [125I]gA  uptake.  D-glucose alone at con- 
centrations of  45 and 90 mM was equally effective. The com- 
petitive  effects  of  albumin  and  glucose  appeared  to  be 
additive  since  their  concomitant  administration  virtually 
abolished the binding of radioiodinated gA. A similar strong 
inhibition was obtained with gA. The effect of either man- 
nose or galactose was negligible (Fig. 2). 
Competition of gA-Au Binding and Transport. The up- 
take of gA-Au was competed with concentrations of albumin 
(20 or 40 ~tg), glucose (45 or 90 mM), or gA (100 I~g) ex- 
pected to be optimally efficient  on the basis of  the radioassays 
already described. Albumin competed primarily for gA-Au 
labeling of plasmalemmal vesicles (Fig. 6). Both the number 
of labeled vesicles and the linear density of label showed an 
approximate fourfold reduction (Tables I and II). In contrast, 
albumin did not affect significantly the labeling density of 
plasmalemma proper and coated pits (Tables I and II). 
Competition with glucose gave essentially complementary 
results; the labeling of  the plasmalemma proper was substan- 
tially reduced (by 60% of control) whereas the gA-Au bind- 
ing to vesicles was only marginally affected (Fig. 7, A and 
B; and Tables I and II). 
When either gA or albumin and glucose administered con- 
comitantly were used as competitors, the labeling of all plas- 
malemmal microdomains (vesicles included) was drastically 
diminished up to abolition (Tables I and II; data not shown). 
Labeling of MVB measured at 30 min of gA-Au perfusion 
showed that endocytosis of this ligand showed an approxi- 
mately threefold reduction by competition with either gA or 
albumin and glucose concomitantly administered (Table III). 
Transcytosis of gA-Au in the presence of albumin or gA 
is largely reduced; after 30-min tracer perfusion, only rare 
particles were seen in abluminal plasmalemmal vesicles (ap- 
parently in fluid phase) and in the subendothelial space. The 
transendothelial transport of the ligand seemed insignificant- 
ly affected by glucose (findings not illustrated). 
Figure 6. The effects on the binding of gA-Au of competition with albumin (40 Ixg/ml). Competition does not affect the binding of the 
tracer to the plasmalemma proper (short arrows) and the infundibula leading to the vesicles (long arrows), but reduces considerably the 
labeling of plasmalemmal vesicles (V,, V2). s, subendothelial space; l, lumen. Bar, 0.1  ~m. 
Predescu et al.  Endothelial  Transport of Glycoalbumin  1735 Figure 7. The effects  on the binding of gA-Au of competition with D-glucose. (45 mM, A and 90 mM, B) Competition markedly reduces 
the gA-Au binding to plasmalemma proper (short arrows) without affecting  significantly  the extent and linear density of labeling of plas- 
malemmal vesicles (V~, V2). In A an endosome (en) and an MVB (mv) are already marked by gA-Au complexes at this early time point 
(3 min). s, subendothelial space; l, lumen; bl, basal lamina. Bars, 0.1 lUn. 
Discussion 
Our  previous  findings  (17, 37)  and  the  comparative  data 
reported in this paper indicate that the interaction of gA with 
the microvascular endothelium is quantitatively and qualita- 
tively different from that of native,  nonglycated albumin. 
The difference applies to both the uptake of monomeric ra- 
dioiodinated ligands and to the binding and transport of the 
polymeric gold-conjugated albumin or gA. Despite the dif- 
ferences between the monomeric albumins (native albumin 
or gA) and their polymeric gold complexes, their binding 
and transport by endothelium is influenced in the same sense 
by the competitors used. 
The uptake of radioiodinated gA perfused for 3 min was 
2.4-fold higher than that of radiolabeled albumin (Fig. 2). 
Morphometric data show that, after 3-min perfusion, while 
A-Au complexes bind almost exclusively to plasmalemmal 
vesicles, gA-Au particles appear firmly and extensively at- 
tached both  to the  luminal plasmalemma proper  and the 
membrane of plasmalemmal vesicles open on the luminal 
front. In contrast to A-Au, gA-Au also decorates a substan- 
tial fraction of coated pits. 
Uptake of 12SI-gA is reduced by •60%  by either albumin 
or glucose but is almost completely abolished by albumin 
and glucose (perfused concomitantly), and to a nearly simi- 
lar extent, by gA. The results obtained in the dual competitor 
experiments suggest that gA behaves as a bifunctional ligand 
which interacts with two separate binding sites on the en- 
dothelial cell surface. These findings are supported by the 
gA-Au  observations  which  reveal  that different microdo- 
mains of endothelial membrane have distinct sensitivities to 
the  competitors  used  in  our experiments:  while albumin 
reduces substantially the labeling of plasmalemmal vesicles 
without affecting the decoration of plasmalemma proper, 
glucose largely prevents the gA-Au binding only to plas- 
malemma proper and coated pits, and not to vesicles. The 
almost complete inhibition of labeling when both competi- 
tors are simultaneously  used shows that albumin and glucose 
have additive effects. These competition experiments suggest 
that the endothelial cell membrane has two distinct classes 
of binding sites:  one, on the plasmalemmal vesicles, recog- 
nizes certain domain(s) of the albumin molecule, whereas 
the other, on the plasmalemma proper, interacts like a lectin 
with the hexose residues of gA.  It appears that conforma- 
tional changes introduced in the gA molecule by either radio- 
iodination or adsorption on gold particles preclude neither 
the ligand interaction(s) with its cognate binding sites nor its 
displacement by competitors. 
gA-Au Transcytosis 
Our findings indicate that the ligand gA-Au is transported in 
time to the pericapillary  spaces and is  restricted to plas- 
malemmal vesicle profiles while in transit through the en- 
dothelium. These profiles may represent either isolated vesi- 
cles  or  sections  through  transendothelial  channels.  The 
interpretation is in keeping with variations in particle density 
per discharging vesicular profile; i.e., a high density (Fig. 
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exit through the intercellular  junctions. The tracer is detected 
in the pericapillary spaces beginning with 3 min and in- 
creases progressively in amounts up to 30 min. We believe 
that our findings establish convincingly the involvement of 
plasmalemmal vesicles in the transport of the tracer, but we 
recognize that our data do not allow a reliable assessment of 
the amount and rate of gA-Au transport.  By comparison, 
both parameters appear to be greater than in the case of  A-Au 
complexes. 
Transcytosis in our experiments can be affected by a num- 
ber of factors including low concentration of albumin in the 
perfusate, number of albumin molecules per gold particle 
and the size of the gA-Au complex. These parameters are ex- 
pected either to accelerate or slow down transcytosis to an 
unknown extent. Transport of monomeric albumin in per- 
fused  myocardial capillaries  appears  to  be  considerably 
faster (25).  According to its dimensions, which range from 
6 to 11 nm, the gA-Au complexes qualify as probes for both 
the small and large pore systems postulated in the capillary 
physiology literature  (for  review  see  reference  32).  Our 
findings implicate the plasmalemmal vesicles of the endo- 
thelium as the structural equivalent of both pore systems. In 
the pericapillary spaces, the tracer appears concentrated in 
the basal lamina in areas in phase with high concentration 
of  abluminal plasmalemmal vesicles. The results of  our com- 
petition  experiments  suggest  that  albumin  binding  sites 
rather than glucose binding sites are primarily involved in 
transcytosis. 
Endocytosis 
gA-Au complexes were found in coated pits, polymorphic 
uncoated vesicles,  presumably endosomes,  and MVB as- 
sumed to be either endosomes or lysosomes. The number of 
labeled MVB and the gA-Au concentration therein increased 
with time. Our data do not permit a reliable quantitation of 
transcytosed vs.  endocytosed tracer, but they strongly sug- 
gest that transcytosis is considerably more active than endocy- 
tosis. 
Integration with the Literature 
Uptake and discharge of albumin vs. gA was studied on iso- 
lated microvessel fragments by Williams et al. (47-49). The 
two operations (uptake-discharge) were interpreted as vesic- 
ular transport, but the involvement of  plasmalemmal vesicles 
in the process studied was not directly proved. A-Au and 
gA-Au were used in perfused lung preparations by Villaski 
et al.  (42) who reported limited transcytosis and extensive 
endocytosis by the capillary endothelium for both tracers. 
The partial lack of agreement between their results and ours 
probably reflects differences in protocol, especially concern- 
ing the amount of tracer used. 
We believe that our findings presented in this and previous 
papers (17, 25, 37) establish convincingly the participation of 
vesicles  in  the  transport  of albumin,  A-Au,  and  gA-Au 
across the endothelium. In this respect they are not in agree- 
ment with the conclusions Bundgaard et al. (6) and Frojkaer- 
Jensen (13) have drawn from their three-dimensional recon- 
struction  of plasmalemmal  vesicles.  These  authors  have 
found that the great majority of plasmalemmal vesicles are 
part of sessile structures associated with one or the other side 
of the endothelium with practically no vesicle left free in the 
cytoplasm. Since such free vesicles were assumed to be a 
prerequisite for transport, the authors claimed that vesicular 
transport cannot exist. Our studies illustrate the advantage of 
integrated functional and morphological approaches which 
monitor the pathway followed by recognizable particulate 
tracers during transport across the endothelium. We con- 
sider that this approach provides more reliable data than a 
strictly morphological analysis of the vesicular system which 
can be affected by the inherent small size of the sampling ex- 
amined and by vesicle redistribution during the slow process 
of chemical fixation. 
There are numerous reports in the literature concerning 
the increased microvascular permeability (including perme- 
ability for macromolecules) in diabetes (10, 11,  16, 30, 41). 
There is also an extensive literature bearing on pathological 
changes of the vasculature in diabetes. The large fraction of 
gA found in diabetes may play a role in these physiopatho- 
logic changes (5,  24,  46,  50).  Our  findings support  in a 
qualitative way the assumption that endothelial permeability 
for gA is increased. Yet it is difficult  to extrapolate from these 
short-range experimental findings to the vascular pathology 
of diabetes which is most probably the result of long term 
chronic alterations in the vessel wall functions, permeability 
included. 
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